Loading
companiesCompany
Dizal Pharmaceutical
Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia.
Also called: Dizal PharmaceuticalsDizal (Jiangsu) Pharmaceutical Co., Ltd.迪哲医药
Overview
Dizal Pharmaceutical, based in Shanghai and listed in Shanghai, designs small-molecule drugs for cancer and immune disease. Its oncology pipeline centres on sunvozertinib, an EGFR inhibitor designed for exon 20 insertion mutations in non-small-cell lung cancer, and DZD8586, an oral inhibitor of LYN and BTK that crosses the blood-brain barrier and is being compared with investigator's choice therapy in relapsed or refractory chronic lymphocytic leukaemia. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#141of 1244 companies, score 41
- approved products +12
- phase 3 +3
- targets +4
- modalities +2
- regions +2
- 24-month regulatory events +2
- registry trials +16
2 approved, 1 in phase 3, 0 earlier, 2 targets, 61 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedSmall-molecule EGFR exon 20 insertion TKI (irreversible)
Sunvozertinib · Zegfrovy
An oral drug for EGFR exon 20 insertion lung cancer that succeeded where mobocertinib failed; approved in China (2023) and the US (2025).
Phase 3small molecule
DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.
ApprovedOral selective JAK1 inhibitor
Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.
Similar pages
cancers
fronts
drugs
Phase 3small molecule
ApprovedOral selective JAK1 inhibitor
ApprovedSmall-molecule EGFR exon 20 insertion TKI (irreversible)
Sunvozertinib · Zegfrovy
trials
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid TumorsA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 InsA Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCPerioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)